MMI270

An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity. MMI270 inhibits a broad spectrum of matrix… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2013
012320012013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Matrix metalloproteinases (MMP) have been implicated in several steps of tumor metastasis, such as invasion in the extracellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2006
2006
We have investigated the antitumor effects of synthetic MMP inhibitor MMI270 against postoperative lung metastasis from colon… (More)
Is this relevant?
2006
2006
Alport syndrome is a glomerular basement membrane (GBM) disease caused by mutations in type IV collagen genes. A unique irregular… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Pulmonary fibrosis is characterized by a loss of lung epithelial cells, replaced by interstitial myofibroblasts to deposit… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
Based on a previous report on the effect of a matrix metalloproteinase (MMP) inhibitory compound, MMI270, in regulating tumor… (More)
Is this relevant?
2004
2004
The orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumour growth metastasis in preclinical models. We… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2004
2004
Circulating endothelial progenitor cell (EPCs) have been reported to contribute to vasculogenesis in adult organisms. To… (More)
Is this relevant?
2003
2003
We investigated the anti-angiogenic effects of a matrix metalloproteinase inhibitor, (MMI), so called MMI270, against B16-BL6… (More)
Is this relevant?
2003
2003
Blood-brain barrier (BBB) disruption is a critical event leading to vasogenic brain edema and secondary brain damage after cold… (More)
Is this relevant?
2001
2001
This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
Is this relevant?